You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: inhaled corticosteroids slow the progression of airflow limitation in COPD

https://doi.org/10.1136/ebm.9.3.75

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Sutherland ER, Allmers H, Ayas NT, et al. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003;58:937–41.
    OpenUrlAbstract/FREE Full Text

    
 
 Q In patients with chronic obstructive pulmonary disease (COPD), do inhaled corticosteroids (ICSs) reduce the progression of airflow limitation?

    Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★☆☆ Respirology ★★★★★☆☆

    METHODS

    Embedded ImageData sources:

    Medline (1966 to February 2003), CINAHL (1982 to February 2003), International Pharmaceutical Abstracts (1970 to February 2003), and the Cochrane Controlled Trials Register, references of retrieved articles, and experts in the field.

    Embedded ImageStudy selection and assessment:

    full reports of randomised controlled trials of ICSs in patients with COPD, had ⩾1 year of follow up, examined change in FEV1 over time, patients with asthma were excluded, and patients were studied when COPD was stable.

    Embedded ImageOutcomes:

    progression of airflow limitation measured by annual rate of change in FEV1.

    MAIN RESULTS

    8 trials (n = 3715) were included. All trials were ⩾2 …

    View Full Text

    Footnotes

    • For correspondence: Dr E R Sutherland, National Jewish Medical and Research Center and the University of Colorado Health Sciences Center, Denver, CO, USA. sutherlandenjc.org

    • Sources of funding: National Institutes of Health and Wellcome Trust.